SHOULDER INNOVATIONS, INC.

SI's capital structure is characterized by a low debt-to-equity ratio of 0.11, indicating a conservative leverage profile. The company holds $11.49 million in cash and equivalents, but its operating cash flow is negative at -$12.36 million, and free cash flow is -$15.09 million, reflecting ongoing operational losses. The current ratio of 11.81 suggests strong short-term liquidity, but the negative net cash position after subtracting total debt raises concerns about long-term liquidity. Profitability metrics are weak, with a net loss of $8.38 million and an operating loss of $8.98 million in Q1 2026. Return on equity (ROE) is -6.3%, and return on assets (ROA) is -5.23%, both significantly below industry norms for medical device firms. Gross profit margin is 77.7%, which is in line with the industry, but operating margin is -53.7%, indicating high operating costs relative to revenue. SI's revenue is concentrated in a single product line: implant systems and instrument trays for shoulder surgery. The company has not disclosed geographic revenue breakdowns, but its focus on U.S. healthcare providers and ASCs suggests a domestic revenue concentration. The efficient instrument system is a key differentiator, but the company's reliance on a narrow product portfolio increases exposure to demand forecasting risks. Growth trajectory is mixed. Revenue increased to $16.71 million in Q1 2026 from $6.37 million in cash and equivalents at the start of the year, but the company's net loss widened compared to the prior year. Capital expenditures of $2.74 million suggest ongoing investment in infrastructure, but the company's cash position has declined by $15.38 million year-over-year. The IPO in August 2025 provided $64.21 million in net proceeds, but this has been largely offset by operating and investing cash outflows. Risk factors include liquidity constraints, with negative operating cash flow and a declining cash balance. The risk assessment flags dilution as medium, citing potential offerings or equity-based compensation. The company's forward-looking statements highlight risks related to demand forecasting, inventory management, and macroeconomic conditions. The dilution potential is supported by the company's recent IPO and the presence of convertible preferred stock. Recent events include the completion of the IPO in August 2025, which raised $64.21 million. The company has also issued forward-looking statements about growth in the shoulder surgical care market, particularly in ASCs. The 10-Q filing includes a warning about the risks of inaccurate demand forecasting and inventory management, which could materially harm operations.